Edgar Filing: NEKTAR THERAPEUTICS - Form 4/A

NEKTAR THE	ERAPEUTICS								
Form 4/A									
January 15, 20	16								
FORM	4		GEGU						PPROVAL
	UNITED	STATES		RITIES AF Ishington, l			COMMISSIO	N OMB Number:	3235-0287
Check this box if no longer subject to Section 16. Form 4 or				IANGES IN BENEFICIAL OWNERSHIP OF SECURITIES			Estimated burden hoi	Estimated average burden hours per	
Form 5 obligations may continu <i>See</i> Instruct 1(b).	Bection 17	(a) of the l	Public U		ing Com	pany Act	nge Act of 1934, of 1935 or Secti 940		. 0.5
(Print or Type Res	ponses)								
1. Name and Add ROBIN HOW		Person <u>*</u>	Symbol	er Name and AR THERA R]		-	Issuer	of Reporting Per eck all applicabl	
(Last) C/O NEKTAF THERAPEUT BAY BOULE	R TICS, 455 MIS			of Earliest Tra Day/Year) 2015	Insaction		below)	ive title Oth below) resident & CEO	% Owner her (specify
SAN FRANC	(Street) ISCO, CA 941	58		endment, Date onth/Day/Year) 2015	-		Applicable Line) _X_ Form filed by	Joint/Group Fili y One Reporting P y More than One R	erson
(City)	(State)	(Zip)	Tab	ole I - Non-De	erivative S	Securities A	cquired, Disposed	of, or Beneficia	lly Owned
	Transaction Date Ionth/Day/Year)		Date, if	Transaction/ Code I	Disposed c Instr. 3, 4	A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerce Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Un	⁻ (1)	12/15/2015		А	67,500	(2)	12/14/2023	Common Stock	67,500
Stock Option	\$ 15.55	12/15/2015		А	56,250	(3)	12/14/2023	Common Stock	56,250

Edgar Filing: NEKTAR THERAPEUTICS - Form 4/A

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
ROBIN HOWARD W C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO, CA 94158	Х		President & CEO		
Signatures					

•	
Gil M. Labrucherie,	01/15/001/
Attorney-in-Fact	01/15/2016

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each restricted stock unit represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.

(2) This restricted stock unit vests over 3 years in equal quarterly installments.

(3) This stock option vests in equal monthly installments over the 4-year period following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.